热门资讯> 正文

血管性脑白质研究入组完成后，intlia上升

2025-09-19 00:25

Intellia Therapeutics (NASDAQ:NTLA) shares jumped after it said that it has finished enrolling participants in its late-stage study of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema.
The shares are up 20.6% so far today.
The results are anticipated in early 2026.
The company plans to submit a biologics license application later in 2026, aiming for a U.S. launch in early 2027.
The first patient was treated in the study in January 2025.

More on Intellia Therapeutics

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript
With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'
ARK Investment buys 560K shares of Intellia Therapeutics
Intellia targets 1,200 patients in expanded Phase III ATTR cardiomyopathy trial as enrollment accelerates

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。